Last updated on July 2019

Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis

Brief description of study

This phase II study will evaluate the safety of combining intermediate frequency electric field (TT Field) with immunotherapy in melanoma patients with brain metastasis. The data of this study will also inform whether this combination will offer advantage in progression free survival (PFS) and overall survival.

Clinical Study Identifier: NCT03903640

Find a site near you

Start Over